Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity

Todd A. Hembrough, Jose F. Ruiz, Bonnie M. Swerdlow, Glenn M. Swartz, Hans J. Hammers, Li Zhang, Stacy M. Plum, Mark S. Williams, Dudley K. Strickland, Victor S. Pribluda

Research output: Contribution to journalArticle

Abstract

Tissue factor pathway inhibitor (TFPI) is the major physiologic inhibitor of the extrinsic coagulation pathway. We have previously shown that TFPI is also a potent inhibitor of endothelial proliferation in vitro and of primary and metastatic tumor growth in vivo. Surprisingly, the antitumor activity of TFPI was demonstrated to be independent of its anticoagulant activity, suggesting a possible nonhemostatic mechanism of action for TFPI in these models. This antitumor mechanism may involve the very low density lipoprotein (VLDL) receptor because the in vitro antiproliferative activity of TFPI is mediated through interaction with the VLDL receptor. In the current study, we identify a 23-amino acid fragment of TFPI (TFPIc23) localized to the C-terminus, which mediates binding to the VLDL receptor. The TFPIc23 peptide inhibits endothelial cell proliferation through an apoptotic mechanism and blocks vessel outgrowth in the in vitro assays, and this activity is mediated through interaction with the VLDL receptor. In vivo, this peptide potently inhibits angiogenesis in Matrigel and chick chorioallantoic membrane models and also inhibits metastatic tumor growth. Our data demonstrate that this VLDL receptor-binding fragment of the TFPI molecule has apoptotic, antiangiogenic, and antitumor activity and suggests a possible mechanism whereby TFPI can regulate angiogenesis and tumor growth independently of its anticoagulant activity.

Original languageEnglish (US)
Pages (from-to)3374-3380
Number of pages7
JournalBlood
Volume103
Issue number9
DOIs
StatePublished - May 1 2004
Externally publishedYes

Fingerprint

Peptides
Tumors
Anticoagulants
Growth
Chorioallantoic Membrane
Neoplasms
lipoprotein-associated coagulation inhibitor
VLDL receptor
Endothelial cells
Cell proliferation
Coagulation
Assays
Endothelial Cells
Cell Proliferation
Membranes
Amino Acids
Molecules
In Vitro Techniques

ASJC Scopus subject areas

  • Hematology

Cite this

Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity. / Hembrough, Todd A.; Ruiz, Jose F.; Swerdlow, Bonnie M.; Swartz, Glenn M.; Hammers, Hans J.; Zhang, Li; Plum, Stacy M.; Williams, Mark S.; Strickland, Dudley K.; Pribluda, Victor S.

In: Blood, Vol. 103, No. 9, 01.05.2004, p. 3374-3380.

Research output: Contribution to journalArticle

Hembrough, TA, Ruiz, JF, Swerdlow, BM, Swartz, GM, Hammers, HJ, Zhang, L, Plum, SM, Williams, MS, Strickland, DK & Pribluda, VS 2004, 'Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity', Blood, vol. 103, no. 9, pp. 3374-3380. https://doi.org/10.1182/blood-2003-07-2234
Hembrough, Todd A. ; Ruiz, Jose F. ; Swerdlow, Bonnie M. ; Swartz, Glenn M. ; Hammers, Hans J. ; Zhang, Li ; Plum, Stacy M. ; Williams, Mark S. ; Strickland, Dudley K. ; Pribluda, Victor S. / Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity. In: Blood. 2004 ; Vol. 103, No. 9. pp. 3374-3380.
@article{0209cfbfc92740d8a1d6268508261713,
title = "Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity",
abstract = "Tissue factor pathway inhibitor (TFPI) is the major physiologic inhibitor of the extrinsic coagulation pathway. We have previously shown that TFPI is also a potent inhibitor of endothelial proliferation in vitro and of primary and metastatic tumor growth in vivo. Surprisingly, the antitumor activity of TFPI was demonstrated to be independent of its anticoagulant activity, suggesting a possible nonhemostatic mechanism of action for TFPI in these models. This antitumor mechanism may involve the very low density lipoprotein (VLDL) receptor because the in vitro antiproliferative activity of TFPI is mediated through interaction with the VLDL receptor. In the current study, we identify a 23-amino acid fragment of TFPI (TFPIc23) localized to the C-terminus, which mediates binding to the VLDL receptor. The TFPIc23 peptide inhibits endothelial cell proliferation through an apoptotic mechanism and blocks vessel outgrowth in the in vitro assays, and this activity is mediated through interaction with the VLDL receptor. In vivo, this peptide potently inhibits angiogenesis in Matrigel and chick chorioallantoic membrane models and also inhibits metastatic tumor growth. Our data demonstrate that this VLDL receptor-binding fragment of the TFPI molecule has apoptotic, antiangiogenic, and antitumor activity and suggests a possible mechanism whereby TFPI can regulate angiogenesis and tumor growth independently of its anticoagulant activity.",
author = "Hembrough, {Todd A.} and Ruiz, {Jose F.} and Swerdlow, {Bonnie M.} and Swartz, {Glenn M.} and Hammers, {Hans J.} and Li Zhang and Plum, {Stacy M.} and Williams, {Mark S.} and Strickland, {Dudley K.} and Pribluda, {Victor S.}",
year = "2004",
month = "5",
day = "1",
doi = "10.1182/blood-2003-07-2234",
language = "English (US)",
volume = "103",
pages = "3374--3380",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity

AU - Hembrough, Todd A.

AU - Ruiz, Jose F.

AU - Swerdlow, Bonnie M.

AU - Swartz, Glenn M.

AU - Hammers, Hans J.

AU - Zhang, Li

AU - Plum, Stacy M.

AU - Williams, Mark S.

AU - Strickland, Dudley K.

AU - Pribluda, Victor S.

PY - 2004/5/1

Y1 - 2004/5/1

N2 - Tissue factor pathway inhibitor (TFPI) is the major physiologic inhibitor of the extrinsic coagulation pathway. We have previously shown that TFPI is also a potent inhibitor of endothelial proliferation in vitro and of primary and metastatic tumor growth in vivo. Surprisingly, the antitumor activity of TFPI was demonstrated to be independent of its anticoagulant activity, suggesting a possible nonhemostatic mechanism of action for TFPI in these models. This antitumor mechanism may involve the very low density lipoprotein (VLDL) receptor because the in vitro antiproliferative activity of TFPI is mediated through interaction with the VLDL receptor. In the current study, we identify a 23-amino acid fragment of TFPI (TFPIc23) localized to the C-terminus, which mediates binding to the VLDL receptor. The TFPIc23 peptide inhibits endothelial cell proliferation through an apoptotic mechanism and blocks vessel outgrowth in the in vitro assays, and this activity is mediated through interaction with the VLDL receptor. In vivo, this peptide potently inhibits angiogenesis in Matrigel and chick chorioallantoic membrane models and also inhibits metastatic tumor growth. Our data demonstrate that this VLDL receptor-binding fragment of the TFPI molecule has apoptotic, antiangiogenic, and antitumor activity and suggests a possible mechanism whereby TFPI can regulate angiogenesis and tumor growth independently of its anticoagulant activity.

AB - Tissue factor pathway inhibitor (TFPI) is the major physiologic inhibitor of the extrinsic coagulation pathway. We have previously shown that TFPI is also a potent inhibitor of endothelial proliferation in vitro and of primary and metastatic tumor growth in vivo. Surprisingly, the antitumor activity of TFPI was demonstrated to be independent of its anticoagulant activity, suggesting a possible nonhemostatic mechanism of action for TFPI in these models. This antitumor mechanism may involve the very low density lipoprotein (VLDL) receptor because the in vitro antiproliferative activity of TFPI is mediated through interaction with the VLDL receptor. In the current study, we identify a 23-amino acid fragment of TFPI (TFPIc23) localized to the C-terminus, which mediates binding to the VLDL receptor. The TFPIc23 peptide inhibits endothelial cell proliferation through an apoptotic mechanism and blocks vessel outgrowth in the in vitro assays, and this activity is mediated through interaction with the VLDL receptor. In vivo, this peptide potently inhibits angiogenesis in Matrigel and chick chorioallantoic membrane models and also inhibits metastatic tumor growth. Our data demonstrate that this VLDL receptor-binding fragment of the TFPI molecule has apoptotic, antiangiogenic, and antitumor activity and suggests a possible mechanism whereby TFPI can regulate angiogenesis and tumor growth independently of its anticoagulant activity.

UR - http://www.scopus.com/inward/record.url?scp=11144357000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144357000&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-07-2234

DO - 10.1182/blood-2003-07-2234

M3 - Article

C2 - 14739228

AN - SCOPUS:11144357000

VL - 103

SP - 3374

EP - 3380

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -